Daily read · 18:00

GLP-1s surprise, brain aging shifts, and concussion gets granular

GLP-1s are showing impacts beyond just weight, our understanding of brain aging is getting complicated, and sports medicine is digging deep into concussion recovery.

Abstract cream-and-slate line illustration on Kokorology paper, drawn for GLP-1s surprise, brain aging shifts, and concussion gets granular

GLP-1s are showing impacts beyond just weight, our understanding of brain aging is getting complicated, and sports medicine is digging deep into concussion recovery.

In today's read: 1. GLP-1's Expanding Reach and Nuance · 2. The Unpredictable Brain: Aging & Recovery · 3. Policy Grapples with AI and Access · 4. Rethinking Preventative Screening

1. GLP-1's Expanding Reach and Nuance

These metabolic drugs are affecting inflammation, cellular aging, and even skin conditions, suggesting their utility is broader than simple weight loss or blood sugar control. We're seeing biological aging metrics shift and new benefits emerge, but individual response varies widely.

Watch for more off-label use and new indications as the 'longevity drug' narrative picks up. Companies will chase these expanded benefits, but expect pushback on one-size-fits-all dosing as patient variability becomes clear.

Evidence from today:

  • GLP-1s cut mortality for acne inversa patients with metabolic conditions — Deutsches Ärzteblatt — Researchers at the University of Lübeck found that GLP-1 medications significantly reduced all-cause mortality in people with hidradenitis suppurativa (acne inversa) who also had type 2 diabetes or obesity. This retrospective cohort study hints at a broader benefit beyond weight loss or blood sugar control, linking GLP-1s to reduced inflammation. It's a signal that these drugs might do more than manage metabolic symptoms.
  • GLP-1s linked to two to three years younger biological age — MIT Tech Review — New research presented at an aging conference suggests GLP-1 weight-loss drugs may reduce biological age by two to three years in overweight and diabetic individuals. This finding is an early signal that these medications could have longevity benefits beyond weight loss and blood sugar control. It points to a broader impact on cellular health.
  • Lower-dose tirzepatide works for weight maintenance, but not for everyone — The Lancet — New correspondence in The Lancet highlights that while lower doses of tirzepatide (5mg) help maintain weight loss more than placebo, the individual response varies widely. Researchers point out that the SURMOUNT-MAINTAIN trial's average results obscure who benefits most and who still regains weight. It's a reminder that a one-size-fits-all approach to GLP-1s might be missing the point.
  • Retatrutide shows strong weight loss for type 2 diabetes — The Lancet — The Lancet published findings from the TRIUMPH-2 study on retatrutide, a triple-agonist (GLP-1, GIP, glucagon) for people with obesity and type 2 diabetes. The phase 3 trial showed superior weight-lowering effects, challenging the idea that GLP-1 response is weaker in this group. It's a big move for metabolic health management.

2. The Unpredictable Brain: Aging & Recovery

New research is overturning old assumptions about brain aging and concussion recovery. Human brains might shrink differently from other primates, and 'don't look at screens' is out for teen concussions. This challenges fixed ideas about nervous system resilience and repair.

Brain health interventions will need to get smarter and more targeted. Expect more push to customize recovery protocols based on individual patient data, especially in sports, as blanket advice proves ineffective or even counterproductive.

Evidence from today:

  • Chimp and gorilla brains don't shrink with age like ours do — Nature News — New research published in Nature shows that while human brains naturally lose mass with age, chimpanzee and gorilla brains largely maintain their size. The study, led by Dr. Chet C. Sherwood, analyzed MRI scans from over 200 primates and suggests human brain aging patterns might be unique, not a universal primate trait.
  • Moderate screen time speeds concussion recovery in teens — BJSM (British Journal of Sports Medicine) — New research in BJSM from lead author Dr. Brenda Porter found that 120-240 minutes of daily screen time actually sped up symptom resolution in 11-17 year olds recovering from a concussion. This goes against the common advice to avoid screens completely. The study, involving over 400 youth, found those with moderate use recovered 2.27x faster than minimal users.
  • OTC pain relievers speed concussion recovery — BJSM (British Journal of Sports Medicine) — New peer-reviewed research in BJSM found that people who took over-the-counter pain relievers after a concussion returned to unrestricted play 24.5% faster. These individuals also reported 30.3% lower overall symptoms and 11.1% lower headache severity. The study, from the CARE Consortium, looked at a large cohort to link early analgesic use to better outcomes.
  • Vision Therapy Works for Concussion-Related Eye Issues — BJSM (British Journal of Sports Medicine) — A new BJSM study found office-based vision therapy remediated accommodative dysfunction in 86% of concussion patients, compared to 28% in a watchful waiting group. The CONCUSS trial suggests that 12 sessions of vision rehabilitation with movement significantly improve eye focus problems after a head injury. Early treatment matters for getting vision back on track post-concussion.

3. Policy Grapples with AI and Access

Regulators and policymakers are struggling to keep pace with rapid innovation in health tech, especially AI, while also trying to fix fundamental access issues. There's a tension between wanting to streamline drug development and ensuring ethical deployment, alongside big gaps in basic care for many.

Expect more calls for proactive AI regulation, not reactive. Health systems globally will continue to face funding pressure, leading to messy compromises on care delivery and persistent health equity gaps as tech advances without a clear policy roadmap.

Evidence from today:

  • Global network forms to vet AI health tools — Nature Medicine RSS — Researchers from 35 institutions across 15 countries launched MAGIC, an international network to test generative AI models in global health. The goal is to ensure these AI tools are safe, effective, and ethically sound for diverse populations, covering diagnostics, mental health support, and treatment plans.
  • Lancet authors call for early regulation of medical AI — The Lancet — A letter in The Lancet argues that medical AI development is outpacing regulation, urging a reversal of the current "develop first, debate later" approach. They want regulators to step in early to shape how AI tools are built for clinical care, before they're already in use.
  • EMA makes clinical trial advice program permanent for drug developers — El Médico Interactivo — The European Medicines Agency (EMA) is making its pilot program for clinical trial application advice permanent, aiming to streamline drug development. This means companies seeking approval for new medicines will get clearer guidance earlier on. A summary report on lessons from 30 applications is due by year-end.
  • Germany backs African pharma with €20M fund to boost drug access — Deutsches Ärzteblatt — Germany's Development Ministry, led by Reem Alabali Radovan, is pouring €20 million into a fund to boost pharmaceutical manufacturing in Africa. This move, announced at the World Health Summit in Berlin, aims to strengthen local drug production, especially for vaccines and other essential medicines. It's about bringing supply chains closer to the populations they serve, building resilience against future health crises.

4. Rethinking Preventative Screening

Some long-held beliefs about universal screening benefits are getting challenged. Colonoscopy, for example, reduces cancer incidence but not necessarily mortality across the board. This highlights the complexity of population-level health interventions and what 'effective' actually means.

This will fuel debate over healthcare resource allocation and personalized screening approaches. Expect more nuanced guidelines that consider individual risk factors, shifting away from blanket recommendations and creating new pathways for early detection.

Evidence from today:

  • NordICC trial says colonoscopy screening reduces cancer incidence, not mortality — The Lancet — A new correspondence in The Lancet, referencing the NordICC trial, indicates that while colonoscopy screening reduces colorectal cancer incidence, it doesn't significantly lower mortality. This finding, from a large study with over 84,000 participants, contrasts with earlier trials on sigmoidoscopy, sparking debate in the medical community about screening effectiveness.
  • NordICC trial: Colonoscopy screening not as effective as thought — The Lancet — The NordICC trial, followed for 13 years, reported that a single offer of colonoscopy screening for ages 55–64 resulted in much lower reductions in colorectal cancer incidence and mortality than expected. Researchers Michal F Kaminski and colleagues published the findings in The Lancet, noting the trial occurred when colonoscopy was already widely used.
  • Colonoscopy cuts cancer rates, but not deaths, says NordICC study — The Lancet — A large, 13-year study published in The Lancet, the NordICC trial, reports that colonoscopy screening reduced colorectal cancer incidence by 18%, but didn't significantly lower mortality rates in the overall screened population. Researchers led by Michal F. Kaminski followed nearly 85,000 adults across Europe. The findings challenge assumptions about the direct life-saving impact of broad screening.
  • Colonoscopy Follow-Up Stretches to Five Years for High-Risk Adenomas — Deutsches Ärzteblatt — A new randomized study in the New England Journal of Medicine suggests that follow-up colonoscopies for high-risk adenomas might be needed only every five years, not three. Researchers found a five-year interval was sufficient, potentially easing the burden on patients and healthcare systems. It's a small but significant shift in prevention, especially for gut health.

Also moved today

New this week in wellness goods

  • FDA clears digital therapeutic for schizophrenia's negative symptoms — Adults with schizophrenia (as adjunct to outpatient care) — The FDA just cleared Motivista, a prescription digital therapeutic from Click Therapeutics, for treating negative symptoms in adults with schizophrenia. It's the first authorized treatment for issues like anhedonia and avolition, tackling symptoms current meds largely miss. This means a new tool for managing brain chemistry that affects motivation and social drive.
  • AgelessRx launches prescription GHK-Cu cream for skin repair — US — AgelessRx dropped a new prescription-strength GHK-Cu cream, available in 0.5% and 3% concentrations. It's pitched for age-related tissue repair and skin renewal, with clinicians guiding the dosage based on patient needs. I see it as another piece of the longevity puzzle making its way to the surface.
  • Kliva offers trail race plans that sync to Garmin — Global — Kliva launched a new app offering pre-built and custom training plans specifically for trail races, designed to sync directly to Garmin devices. It aims to streamline training for runners navigating varied terrain and elevation. The platform uses AI to adapt plans for different race distances and athlete levels.
  • Small Wins launches 14-day audio physiotherapy via WhatsApp — global — Small Wins just dropped "14 gentle mornings," an audio-first physiotherapy program delivered straight to your WhatsApp. It’s a two-week routine focused on morning movement to help with chronic pain, directly from a physio. The idea is to make daily recovery accessible and consistent.
  • Rhem Labs launches robot assistants for elderly parents' health — elderly care/consumer health — Rhem Labs debuted health assistant robots designed to help older adults with daily routines and health monitoring. The system uses sensors and AI to track vital signs, medication adherence, and movement patterns, sending alerts to family members if irregularities are detected. It's meant to reduce caregiver burden and support independent living.
  • Moonwalkers Dusk: Strap-on motorized wheels for double-speed walking — urban commuters — Shift Robotics just launched Moonwalkers Dusk, a new version of their strap-on motorized wheels. The company claims these devices let you walk at twice your normal speed. They're positioning it as a micro-mobility solution for urban commutes.
  • Simple Workout Log launches minimalist workout tracking app — Global — Simple Workout Log, a new app on Product Hunt, offers a bare-bones way to track your strength workouts. It's designed for users who want to log reps, sets, and weights without extra fluff or social features. The app promises a distraction-free experience for consistent training.
  • Aegis launches safety app with 24/7 dispatch — global — Aegis, a new personal safety app, launched offering direct connection to 24/7 dispatch services. It's designed to provide users with a rapid response mechanism in emergencies, aiming to reduce perceived threats and activate help quickly. The app is available on iOS and Android.

Signal map

Europe: 20 · UK & Ireland: 17 · Global: 13 · North America: 7 · Nordics: 2 · Oceania: 2

What I'd watch next

Keep an eye on further GLP-1 research for new longevity and anti-inflammatory mechanisms. Also, observe how healthcare policies adapt to AI's dual role in efficiency and cost, and whether we see more personalized, less prescriptive approaches to health interventions gain traction.

Where this fits at Kokorology

The nervous system is the common thread today: from GLP-1 side effects to concussion recovery and mental health. Understanding its regulation helps make sense of these complex shifts. The Nervous System Journal helps you track and understand your own signals.